The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Molecular diagnostics of gliomas: state of the art
Open accessAbstract
Modern neuropathology serves a key function in the multidisciplinary management of brain tumor patients. Owing to the recent advancements in molecular neurooncology, the neuropathological assessment of brain tumors is no longer restricted to provide information on a tumor's histological type and malignancy grade, but may be complemented by a growing number of molecular tests for clinically relevant tissue-based biomarkers. This article provides an overview and critical appraisal of the types of genetic and epigenetic aberrations that have gained significance in the molecular diagnostics of gliomas, namely deletions of chromosome arms 1p and 19q, promoter hypermethylation of the O6-methylguanine-methyl-transferase (MGMT) gene, and the mutation status of the IDH1 and IDH2 genes. In addition, the frequent oncogenic aberration of BRAF in pilocytic astrocytomas may serve as a novel diagnostic marker and therapeutic target. Finally, this review will summarize recent mechanistic insights into the molecular alterations underlying treatment resistance in malignant gliomas and outline the potential of genome-wide profiling approaches for increasing our repertoire of clinically useful glioma markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Schouten, J. P. (2002) · Nucleic Acids Research · doi:10.1093/nar/gnf056 · Cited by 2,699
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Self-citationBeier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P. J., Aigner, L., Brawanski, A., Bogdahn, U., & Beier, C. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4180 · Cited by 1,153
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 959
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Self-citationMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationJenkins, R. B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 763
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 654
Diffuse glioma growth: a guerilla war
Claes, A., Idema, A. J., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0293-7 · Cited by 636
Self-citationSmith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Self-citationIDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · cited 2×
“, a subset of acute myeloid leukemias with a normal karyotype [23, 103], and occasionally in prostate cancer, B-ALL [23], and paraganglioma [37].”
BackgroundCharacterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balss, J., Habel, A., Meyer, J., Jäger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 526
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Self-citationWikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D. K., Pegram, C. N., & Reist, C. J. (1995) · PubMed · Cited by 518
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Brat, D. J., Castellano-Sanchez, A. A., Hunter, S. B., Pecot, M., Cohen, C., Hammond, E. H., Devi, S. N., Kaur, B., & Van Meir, E. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2073 · Cited by 485
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 452
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 434
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Ino, Y., Betensky, R. A., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Ramsay, D. A., Cairncross, J. G., & Louis, D. N. (2001) · PubMed · Cited by 432
Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 400
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 396
A multigene predictor of outcome in glioblastoma
Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., Popoff, S., Nutt, C. L., Louis, D. N., Cairncross, J. G., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop007 · Cited by 386
van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J. B., Wesseling, P., Frenay, M., Tijssen, C. C., Lacombe, D., Idbaih, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2902 · Cited by 381
Self-citationSmith, J. S., Alderete, B., Minn, Y., Borell, T. J., Perry, A., Mohapatra, G., Hosek, S. M., Kimmel, D., O'Fallon, J., Yates, A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202759 · Cited by 374
Bleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 363
Brat, D. J., & Van Meir, E. G. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700070 · Cited by 330
Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T., Berens, T. J., McDonough, W., Sloan, A., Coons, S. W., & Berens, M. E. (2005) · Neoplasia · doi:10.1593/neo.04535 · Cited by 323
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Pelloski, C. E., Ballman, K. V., Furth, A. F., Zhang, L., Lin, E., Sulman, E. P., Bhat, K., McDonald, J. M., Yung, W. K. A., Colman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0705 · Cited by 311
Griffin, C. A., Burger, P., Morsberger, L., Yonescu, R., Swierczynski, S., Weingart, J. D., & Murphy, K. M. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235122.98052.8f · Cited by 303
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology
Reifenberger, G., & Louis, D. N. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.2.111 · Cited by 296
Self-citationKorshunov, A., Meyer, J., Capper, D., Christians, A., Remke, M., Witt, H., Pfister, S., von Deimling, A., & Hartmann, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0550-z · Cited by 279
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Self-citationFrequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma
Bar, E. E., Lin, A., Tihan, T., Burger, P. C., & Eberhart, C. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181845622 · Cited by 261
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 255
Self-citationBelanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244
EGFR overexpression and radiation response in glioblastoma multiforme
Barker, F. G., Simmons, M. L., Chang, S. M., Prados, M. D., Larson, D. A., Sneed, P. K., Wara, W. M., Berger, M. S., Chen, P., Israel, M. A., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01609-1 · Cited by 243
Mikeska, T., Bock, C., El-Maarri, O., Hübner, A., Ehrentraut, D., Schramm, J., Felsberg, J., Kahl, P., Büttner, R., Pietsch, T., et al. (2007) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060167 · Cited by 239
Heimberger, A. B., Alexander, L. E. C., Archer, G. E., Hess, K. R., Wikstrand, C. J., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2003) · PubMed · Cited by 234
Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., & Loeffler, J. S. (2002) · PubMed · Cited by 234
McEllin, B., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 231
Chinot, O. L., Barrié, M., Fuentes, S., Eudes, N., Lancelot, S., Metellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P.-M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4807 · Cited by 212
Chou, W.-C., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 204
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204
Felsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., Steiger, H.-J., Friedensdorf, B., Reifenberger, G., & Sabel, M. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2801 · Cited by 203
Self-citationVlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., et al. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070169 · Cited by 197
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
van den Bent, M. J., Looijenga, L. H. J., Langenberg, K., Dinjens, W., Graveland, W., Uytdewilligen, L., Sillevis Smitt, P. A., Jenkins, R. B., & Kros, J. M. (2003) · Cancer · doi:10.1002/cncr.11187 · Cited by 196
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
Dubbink, H. J., Taal, W., van Marion, R., Kros, J. M., van Heuvel, I., Bromberg, J. E., Zonnenberg, B. A., Zonnenberg, C. B. L., Postma, T. J., Gijtenbeek, J. M. M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34ace · Cited by 188
Jeuken, J. W. M., Cornelissen, S. J. B., Vriezen, M., Dekkers, M. M. G., Errami, A., Sijben, A., Boots-Sprenger, S. H. E., & Wesseling, P. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700664 · Cited by 180
Self-citationHalatsch, M.-E., Schmidt, U., Behnke-Mursch, J., Unterberg, A., & Wirtz, C. R. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.003 · Cited by 174
Felsberg, J., Erkwoh, A., Sabel, M. C., Kirsch, L., Fimmers, R., Blaschke, B., Schlegel, U., Schramm, J., Wiestler, O. D., & Reifenberger, G. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00044.x · Cited by 173
Self-citationPollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., & Finlay, J. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7265 · Cited by 173
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., & Bigner, D. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.04.001 · Cited by 172
Cheng, C. L., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali-Osman, F., Szabo, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Horbinski, C., Kofler, J., Kelly, L. M., MURDOCH, G. H., & Nikiforova, M. N. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c391be · Cited by 167
Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
Self-citationAnalysis of IDH1 and IDH2 mutations in Japanese glioma patients
Sonoda, Y., Kumabe, T., Nakamura, T., Saito, R., Kanamori, M., Yamashita, Y., Suzuki, H., & Tominaga, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01270.x · Cited by 155
Giannini, C., Burger, P. C., Berkey, B. A., Cairncross, J. G., Jenkins, R. B., Mehta, M. P., Curran, W. J., & Aldape, K. D. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00129.x · Cited by 136
Progressive low‐grade oligodendrogliomas
Levin, N., Lavon, I., Zelikovitsh, B., et al. (2006) · Cancer · doi:10.1002/cncr.21809 · Cited by 134
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 131
Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Gaal, J., Burnichon, N., Korpershoek, E., Roncelin, I., Bertherat, J. Y., Plouin, P., de Krijger, R. R., Gimenez‐Roqueplo, A., & Dinjens, W. N. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2170 · Cited by 131
Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?
The German Glioma Network, Weller, M., Berger, H., Hartmann, C. J., Schramm, J., Westphal, M., Simon, M., Goldbrunner, R., Krex, D., Steinbach, J. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0573 · Cited by 129
Felsberg, J., Wolter, M., Seul, H., Friedensdorf, B., Goeppert, M., Sabel, M., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0647-4 · Cited by 128
Self-citationMolecular pathogenesis of oligodendroglial tumors
Jeuken, J. W. M., von Deimling, A., & Wesseling, P. (2004) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-2748-1 · Cited by 119
Self-citationDevelopment of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples
Yoshimoto, K., Dang, J. H. T., Zhu, S., Nathanson, D. A., Huang, T., Dumont, R. A., Seligson, D. B., Yong, W. H., Xiong, Z., Rao, N. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1966 · Cited by 115
Kato, Y., Jin, G., Kuan, C.-T., McLendon, R. E., Yan, H., & Bigner, D. D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.001 · Cited by 112
Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma
Gravendeel, L. A. M., Kloosterhof, N. K., Bralten, L. B. C., van Marion, R., Dubbink, H. J., Dinjens, W. N. M., Bleeker, F. E., Hoogenraad, C. C., Michiels, E. M. C., Kros, J. M., et al. (2010) · Human Mutation · doi:10.1002/humu.21201 · Cited by 111
Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers
Yip, S. S. F., Iafrate, A. J., & Louis, D. N. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f65fb · Cited by 109
Linz, U. (2010) · Cancer · doi:10.1002/cncr.24950 · Cited by 104
Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma
Dong, S., Nutt, C. L., Betensky, R. A., Stemmer-Rachamimov, A. O., Denko, N. C., Ligon, K. L., Rowitch, D. H., & Louis, D. N. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000186940.14779.90 · Cited by 104
van, Dubbink, Hj, Mariê, Brandes, Aa, TAPHOORN, M. J. B., Mj, Wesseling, P., Frenay, et al. (2010) · 中国神经肿瘤杂志 · Cited by 104
Self-citationSelective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome
Watanabe, T., Vital, A., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0528-x · Cited by 102
McDonald, K. L., McDonnell, J., Muntoni, A., Henson, J. D., Hegi, M. E., von Deimling, A., Wheeler, H., Cook, R. J., Biggs, M. T., Little, N., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e576cf · Cited by 97
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Heimberger, A. B., & Sampson, J. H. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903124346 · Cited by 94
Molecular signatures classify astrocytic gliomas by IDH1 mutation status
Toedt, G., Barbus, S., Wolter, M., Felsberg, J., Tews, B., Blond, F., Sabel, M., Hofmann, S., Becker, N., Hartmann, C. J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25448 · Cited by 91
Self-citationMismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
Maxwell, J. A., Johnson, S. P., McLendon, R. E., Lister, D. W., Horne, K. S., Rasheed, A., Quinn, J. A., Ali‐Osman, F., Friedman, A. H., Modrich, P. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4807 · Cited by 87
Horbinski, C., Kelly, L. M., Nikiforov, Y. E., Durso, M. B., & Nikiforova, M. N. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090228 · Cited by 85
Jeuken, J. W. M., Sijben, A. E. J., Alenda, C., Rijntjes, J., Dekkers, M. M. G., Boots‐Sprenger, S., McLendon, R. E., & Wesseling, P. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00320.x · Cited by 85
Self-citationSurvival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Brandes, A. A. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-005 · Cited by 82
Antonelli, M., Buttarelli, F. R., Arcella, A., Nobusawa, S., Donofrio, V., Oghaki, H., & Giangaspero, F. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0129-5 · Cited by 78
EGF receptor variant III as a target antigen for tumor immunotherapy
Li, G., & Wong, A. J. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.977 · Cited by 74
PCR‐ and Restriction Endonuclease‐Based Detection of IDH1 Mutations
Meyer, J., Pusch, S., Balß, J., Capper, D., Mueller, W. C., Christians, A., Hartmann, C. J., & von Deimling, A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00327.x · Cited by 66
Subtyping of oligo-astrocytic tumours by comparative genomic hybridization
Jeuken, J. W. M., Sprenger, S. H. E., Boerman, R. H., von Deimling, A., Teepen, H. L. J. M., van Overbeeke, J. J., & Wesseling, P. (2001) · The Journal of Pathology · doi:10.1002/path.837 · Cited by 62
Self-citationGlioma-derived mutations in IDH: From mechanism to potential therapy
Fu, Y., Huang, R., Du, J., Yang, R., An, N., & Liang, A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.05.115 · Cited by 57
Seiz, M., Tuettenberg, J., Meyer, J., Essig, M., Schmieder, K., Mawrin, C., von Deimling, A., & Hartmann, C. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0701-2 · Cited by 56
Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance
Weppler, S. A., Li, Y., Dubois, L. J., Lieuwes, N. G., Jutten, B., Lambin, P., Wouters, B. G., & Lammering, G. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.04.025 · Cited by 56
Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma
Ebinger, M., Senf, L., Wachowski, O., & Scheurlen, W. G. (2004) · Pathology & Oncology Research · doi:10.1007/bf02893403 · Cited by 47
Molecular classification of human gliomas using matrix-based comparative genomic hybridization
Roerig, P., Neßling, M., Radlwimmer, B., Joos, S., Wrobel, G., Schwäenen, C., Reifenberger, G., & Lichter, P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21121 · Cited by 42
Self-citationTrost, D., Ehrler, M., Fimmers, R., Felsberg, J., Sabel, M., Kirsch, L., Schramm, J., Wiestler, O. D., Reifenberger, G., & Weber, R. G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22574 · Cited by 39
Self-citationTemozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells
Papait, R., Magrassi, L., Rigamonti, D., & Cattaneo, E. F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.091 · Cited by 38
Preusser, M., Gelpí, E., Rottenfusser, A., Dieckmann, K. U., Widhalm, G., Dietrich, W., Bertalanffy, A., Prayer, D., Hainfellner, J. A., & Marosi, C. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9608-3 · Cited by 31
Can morphology predict 1p/19q loss in oligodendroglial tumours?
Scheie, D., Cvancarova, M., Mörk, S., Skullerud, K., Andresen, P. A., Benestad, I., Helseth, E., Meling, T. R., & Beiske, K. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03160.x · Cited by 30
Prognostic Value of IDH1 Mutations Identified with PCR-RFLP Assay in Glioblastoma Patients
Bujko, M., Kober, P., Matyja, E., Nauman, P., Dyttus‐Cebulok, K., Czeremszynska, B., Bonicki, W., & SIEDLECKI, J. A. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256369 · Cited by 29
Cited by
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
Self-citationExosomes from marrow stromal cells expressing miR-146b inhibit glioma growth
Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., Shu, W., Jiang, F., & Chopp, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.019 · Cited by 681
Capelle, L., Fontaine, D., Mandonnet, E., Taillandier, L., Golmard, J. L., Bauchet, L., Pallud, J., Peruzzi, P., Baron, M. H., Kujas, M., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.1.jns121 · Cited by 422
Ludwig, K., & Kornblum, H. I. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2379-y · Cited by 418
Metadata
- Authors
- Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G.
- Venue
- Acta Neuropathologica
- Published
- 2010-08-17
- Volume
- 120
- Issue
- 5
- Pages
- 567-584
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2164385994
- Cited by
- 283
- References
- 132
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.